Allergic Rhinitis Market
Allergic Rhinitis Market Summary
According to Market Research Future analysis, the Allergic Rhinitis Market Size was valued at USD 12.34 Billion in 2024 & the market is projected to grow from USD 12.8 Billion in 2025 to USD 18.44 Billion by 2035, registering a CAGR of 3.72% during the forecast period 2025–2035. North America led the market with over 39.71% share, generating around USD 4.9 billion in revenue.
Rising prevalence of allergic disorders and increasing exposure to environmental allergens are key growth drivers of the allergic rhinitis market. Growing awareness, improved diagnosis rates, and advancements in treatment options are accelerating demand for effective allergy management solutions globally.
According to WHO, allergic rhinitis affects up to 400 million people globally, while CDC reports that nearly 25% of adults in the U.S. experience seasonal allergies, highlighting strong and growing demand for allergy treatment solutions worldwide.
Key Market Trends & Highlights
The Allergic Rhinitis Market is experiencing dynamic growth driven by environmental factors and advancements in treatment.
- North America accounts for over 39.71% market share in 2024, driven by high allergy prevalence and awareness.
- Europe market valued at USD 3.70 billion in 2024, holding 30% share with rising allergy cases and innovations.
- Allergic rhinitis affects up to 400 million people globally, significantly driving demand for advanced allergy treatment solutions.
- Seasonal allergic rhinitis dominates with 52% share due to increasing pollen exposure and environmental allergen prevalence globally.
Market Size & Forecast
| 2024 Market Size | 12.34 (USD Billion) |
| 2035 Market Size | 18.44 (USD Billion) |
| CAGR (2025 - 2035) | 3.72% |
Major Players
Companies such as GlaxoSmithKline (GB), Boehringer Ingelheim (DE), Sanofi (FR), AstraZeneca(GB), Novartis (CH), Merck & Co. (US), Allergan (US), Bayer (DE), Teva Pharmaceutical Industries (IL) are some of the major participants in the global market.
Allergic Rhinitis Market Trends
The Allergic Rhinitis Market is currently experiencing notable transformations driven by various factors. Increasing awareness regarding the condition, coupled with a rise in environmental allergens, has led to a growing demand for effective treatment options. Patients are becoming more informed about their symptoms and the available therapies, strengthening the allergic rhinitis medication market and influencing evolving market trends.
Furthermore, advancements in pharmaceutical research are contributing to the development of innovative therapies, enhancing patient outcomes and satisfaction while expanding the hay fever allergic rhinitis therapeutics market and broader hay fever and allergic rhinitis therapeutics market. As a result, the market is evolving to meet the diverse needs of individuals suffering from allergic rhinitis.
In addition, the market is witnessing a shift towards more personalized medicine approaches. This trend is characterized by the integration of genetic and environmental factors into treatment plans, allowing for more effective management of the condition and supporting ongoing allergic rhinitis market analysis.
The increasing prevalence of allergic rhinitis across various demographics is also influencing market dynamics, as healthcare systems strive to address this growing public health concern. Overall, the Allergic Rhinitis Market appears poised for continued growth, driven by ongoing research, patient education, and the development of targeted therapies within the allergic rhinitis pipeline drugs market.
Allergic rhinitis is becoming increasingly common worldwide, affecting approximately 10–30% of the global population according to the World Health Organization, which is significantly increasing demand for effective medications and treatment solutions.
Rise in Environmental Allergens
The prevalence of environmental allergens, such as pollen, dust mites, and mold, is increasing, leading to a higher incidence of allergic rhinitis. This trend is prompting a greater focus on preventive measures and treatment options to alleviate symptoms and expanding demand across the allergic rhinitis treatment device market alongside pharmacological solutions.
Environmental factors are a key driver, as studies show that over 400 million people globally suffer from allergic rhinitis due to allergens such as pollen, dust mites, and air pollution, fueling demand for both pharmacological and device-based treatment options.
Advancements in Treatment Options
Innovations in pharmaceutical research are resulting in the development of new therapies for allergic rhinitis. These advancements aim to improve efficacy and patient compliance, thereby enhancing overall treatment outcomes and strengthening the global allergic rhinitis drugs market.
Shift Towards Personalized Medicine
The Allergic Rhinitis Market is gradually moving towards personalized medicine, where treatment plans are tailored to individual patient profiles. This approach considers genetic and environmental factors, potentially leading to more effective management of the condition and accelerating innovation within the allergic rhinitis treatment market.
Pharmaceutical innovation is accelerating in allergy treatment, with global spending on allergy and immunology drug research growing by more than 6% annually, supporting the development of next-generation therapies and personalized treatment approaches.
Allergic Rhinitis Market Drivers
Rising Awareness and Education
Rising awareness and education regarding allergic rhinitis are crucial drivers for the Allergic Rhinitis Market. As healthcare professionals and organizations emphasize the importance of recognizing and managing allergic rhinitis, patients are becoming more informed about their condition. This increased awareness is likely to lead to higher diagnosis rates and, consequently, greater demand for treatment options.
Educational campaigns and resources aimed at both patients and healthcare providers are essential in promoting understanding of allergic rhinitis. The market may witness a surge in demand for over-the-counter medications and prescription therapies as individuals seek relief from symptoms, thereby contributing to the overall growth of the market.
Impact of Climate Change on Allergens
The impact of climate change on allergens is becoming increasingly evident, influencing the Allergic Rhinitis Market. Changes in weather patterns and rising temperatures are contributing to longer pollen seasons and increased allergen exposure. This phenomenon is likely to result in a higher incidence of allergic rhinitis, as more individuals are affected by seasonal allergies.
The market may experience growth as healthcare providers and pharmaceutical companies respond to this trend by developing new treatments and preventive measures. Additionally, the heightened awareness of environmental factors contributing to allergic rhinitis may drive demand for educational resources and innovative solutions within the market.
Technological Advancements in Treatment
Technological advancements in treatment options for allergic rhinitis are transforming the Allergic Rhinitis Market. Innovations such as sublingual immunotherapy and biologics are gaining traction, offering patients more effective and targeted therapies. The introduction of these advanced treatment modalities is likely to enhance patient compliance and satisfaction, as they often present fewer side effects compared to traditional medications.
Furthermore, the market for biologics is projected to grow significantly, with estimates suggesting a compound annual growth rate of over 10% in the next few years. This trend indicates a shift towards more personalized and effective treatment strategies, which could reshape the landscape of the market.
Increase in Allergic Rhinitis Prevalence
The prevalence of allergic rhinitis appears to be on the rise, driven by various environmental factors and lifestyle changes. According to recent estimates, approximately 10 to 30% of the population is affected by this condition, which is expected to increase in the coming years. This growing incidence is likely to propel the Allergic Rhinitis Market, as more individuals seek effective treatment options.
The increasing awareness of allergic rhinitis and its impact on quality of life may also contribute to higher demand for medications and therapies. As healthcare providers recognize the importance of addressing this condition, the market is poised for expansion, with a focus on innovative solutions that cater to the needs of patients suffering from allergic rhinitis.
Growing Demand for Over-the-Counter Products
The growing demand for over-the-counter (OTC) products is a notable trend within the Allergic Rhinitis Market. Many patients prefer OTC medications due to their accessibility and convenience, which allows for self-management of symptoms. The market for OTC antihistamines and nasal sprays has expanded significantly, with sales figures indicating a steady increase in consumer spending on these products.
This trend is likely to continue as more individuals seek immediate relief from allergic rhinitis symptoms without the need for a prescription. The rise in self-medication practices may further bolster the market, as consumers become more proactive in managing their health.
Market Segment Insights
By Type: Seasonal Allergic Rhinitis (Largest) vs. Perennial Allergic Rhinitis (Fastest-Growing)
The market exhibits a diverse segmentation in terms of type, where seasonal allergic rhinitis holds the largest Allergic Rhinitis Market share at 52%, driven by environmental factors such as pollen susceptibility, which affects a significant portion of the population during specific seasons. In contrast, Perennial Allergic Rhinitis, caused mainly by indoor allergens, is witnessing a rapid increase in prevalence, showcasing its growing importance in the market landscape. The Occupational Allergic Rhinitis segment, although smaller, highlights a noteworthy concern for workers exposed to allergenic substances, adding to the complexity of the market.
Seasonal Allergic Rhinitis (Dominant) vs. Occupational Allergic Rhinitis (Emerging)
Seasonal Allergic Rhinitis is recognized as the dominant segment due to its vast impact during peak seasons when allergen levels, particularly pollen, surge and affect millions globally. This segment is primarily characterized by episodic symptoms and a well-established treatment regimen involving antihistamines and nasal corticosteroids. In contrast, Occupational Allergic Rhinitis is an emerging segment influenced by increasing workplace health awareness and regulations. As more individuals are exposed to allergens in occupational settings, the demand for targeted therapies and preventive measures is gaining momentum, making it a significant area of focus for pharmaceutical development and workplace health initiatives.
By Treatment: Antihistamines (Largest) vs. Immunotherapy (Fastest-Growing)
The treatment segment is dominated by antihistamines, which account for a significant Allergic Rhinitis Market share at 46% due to their widespread effectiveness in alleviating symptoms. These medications are preferred by many patients for their rapid onset of action and varied formulations. Following antihistamines, corticosteroids hold a substantial share, catering to patients requiring long-term management of inflammation. Immunotherapy, despite being smaller currently, is gaining traction as it offers a more permanent solution to allergies compared to traditional treatments.
Antihistamines (Dominant) vs. Immunotherapy (Emerging)
Antihistamines remain the dominant force in the allergic rhinitis treatment segment, celebrated for their effectiveness in providing quick relief from sneezing, itching, and other uncomfortable symptoms. These medications are available in various forms, including tablets, nasal sprays, and eye drops, making them easily accessible and convenient for users. On the flip side, immunotherapy is emerging as a promising alternative for long-term relief, particularly in individuals seeking to reduce their allergic response over time. With advancements in sublingual and injectable therapies, immunotherapy is set to capture a growing patient base, signifying a shift towards more sustainable treatment options.
By Route of Administration: Nasal (Largest) vs. Oral (Fastest-Growing)
The market for allergic rhinitis treatments is significantly shaped by the route of administration. Among these, nasal administration has emerged as the largest segment, with a 58% share, capturing a substantial portion due to its rapid onset of action and targeted delivery mechanism. In contrast, oral administration is gaining traction and is noted for its convenience and ease of use, appealing to a broader consumer base, especially among those seeking over-the-counter solutions. Growth trends indicate a shift towards more user-friendly administration routes, with the oral segment poised for robust expansion. Key drivers include increased awareness of allergic rhinitis, advancements in oral drug formulations, and the rising preference for non-invasive treatment options. This dual focus on effective symptom relief and convenience is likely to further boost market engagement in both segments.
Nasal (Dominant) vs. Oral (Emerging)
In the allergic rhinitis market, the nasal route of administration stands as the dominant player, primarily owing to its efficient delivery system that ensures quick alleviation of symptoms. Products such as nasal sprays are favored for their rapid onset and localized action, making them suitable for severe allergic reactions. Conversely, the oral segment is emerging as a strong contender, with innovations leading to more effective formulations that enhance bioavailability and patient adherence. The convenience offered by oral medications appeals to a growing number of individuals, thereby positioning this segment for accelerated growth. While nasal products maintain a strong market presence, the rising demand for versatility in treatment options fosters healthy competition between these two routes.
Regional Insights
North America : Market Leader in Innovation
North America leads in the Allergic Rhinitis Market Size, accounting for over 39.71% of the global revenue in 2024. The region's growth is driven by increasing prevalence of allergies, heightened awareness of treatment options, and robust healthcare infrastructure. Regulatory support for innovative therapies and a strong pipeline of new products further catalyze market expansion.
CDC reports that over 50 million Americans experience various types of allergies annually, making it one of the most common chronic conditions, significantly driving demand for allergic rhinitis treatments and advanced therapeutic solutions.
The U.S. is the primary contributor, followed by Canada, which is experiencing a growing demand for effective allergy management solutions. The competitive landscape in North America is characterized by the presence of major pharmaceutical companies such as Merck & Co., Allergan, and GlaxoSmithKline.
These key players are actively involved in research and development to introduce novel therapies. The market is also witnessing collaborations and partnerships aimed at enhancing product offerings and improving patient outcomes. The focus on personalized medicine and biologics is expected to shape the future of allergic rhinitis treatment in this region.
Europe : Emerging Regulatory Frameworks
Europe Allergic Rhinitis Market size was valued at USD 3.70 Billion in 2024, making it the second-largest regional market with a 30% share. Growth is supported by regulatory initiatives and strong therapeutic innovation, particularly within Europe market by treatment strategies focusing on immunotherapy and advanced biologics.
WHO Europe estimates that allergic conditions affect nearly 30% of the population in the region, with increasing environmental triggers contributing to higher diagnosis rates and growing demand for effective allergic rhinitis management solutions.
Regulatory bodies are actively promoting innovative treatments, which is expected to enhance patient access to effective therapies. Countries like Germany and France are leading the market, supported by strong healthcare systems and increasing healthcare expenditure. The competitive landscape in Europe features key players such as Sanofi, AstraZeneca, and Bayer, who are investing in research to develop advanced treatment options.
The presence of a well-established pharmaceutical industry and ongoing clinical trials for new therapies are significant factors driving market growth. Additionally, the European Medicines Agency's commitment to expediting the approval process for novel therapies is likely to further boost the market landscape.
Asia-Pacific : Rapidly Growing Market Potential
Asia-Pacific is witnessing rapid growth in the allergic rhinitis market, holding approximately 20% of the global share. The region's growth is driven by increasing urbanization, rising pollution levels, and changing lifestyles that contribute to higher allergy prevalence. Countries like China and India are at the forefront, with significant investments in healthcare infrastructure and awareness campaigns aimed at allergy management. Regulatory support for new therapies is also enhancing market dynamics.
The competitive landscape in Asia-Pacific is evolving, with both local and international players vying for market share. Companies such as Teva Pharmaceutical Industries and Boehringer Ingelheim are expanding their presence through strategic partnerships and product launches. The focus on affordable treatment options and the introduction of over-the-counter medications are expected to further drive market growth in this region, catering to the increasing demand for effective allergy solutions.
Middle East and Africa : Untapped Market Opportunities
The Middle East and Africa region is gradually emerging in the allergic rhinitis market, currently holding about 10% of the global share. The growth is primarily driven by increasing awareness of allergic conditions, rising healthcare expenditure, and the need for effective treatment options. Countries like South Africa and the UAE are leading the market, supported by improving healthcare infrastructure and government initiatives aimed at enhancing allergy management.
Regulatory frameworks are evolving to facilitate the introduction of new therapies. The competitive landscape in this region is characterized by a mix of local and international players, with companies like Novartis and Bayer actively participating in market development. The focus on education and awareness campaigns is crucial for driving demand for allergy treatments. Additionally, the increasing prevalence of allergic rhinitis due to environmental factors presents significant opportunities for growth in this untapped market.
Key Players and Competitive Insights
Merck & Co. (US) appears to be concentrating on digital transformation to improve patient engagement and streamline operations, collectively influencing the competitive environment towards a more integrated and patient-centric approach.
The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Allergic Rhinitis Market is moderately fragmented, with a mix of established players and emerging companies. The collective influence of these key players fosters a competitive structure that encourages innovation and responsiveness to consumer needs, thereby driving market growth.
In August 2025, GlaxoSmithKline (GB) announced a collaboration with a leading biotechnology firm to develop a new biologic treatment for allergic rhinitis. This strategic move is significant as it not only diversifies GSK's product offerings but also positions the company at the forefront of innovative treatment solutions, potentially enhancing its competitive edge in a crowded market.
In September 2025, Sanofi (FR) launched a digital health platform aimed at improving patient adherence to allergic rhinitis therapies. This initiative reflects a growing trend towards integrating technology into healthcare, suggesting that Sanofi is keen on leveraging digital tools to enhance patient outcomes and engagement, which could lead to increased market share.
In July 2025, Merck & Co. (US) expanded its manufacturing capabilities in Europe to meet the rising demand for its allergy medications. This expansion is indicative of Merck's commitment to ensuring supply chain reliability and responsiveness, which is crucial in a market where timely access to medications can significantly impact patient health outcomes.
As of October 2025, current competitive trends in the Allergic Rhinitis Market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to foster innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment options, and robust supply chain management, underscoring the importance of reliability and patient-centric solutions in the market.
Key Companies in the Allergic Rhinitis Market include
Industry Developments
November 2020:
In November 2020, Dr Reddys Laboratories announced that it has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine).
April 2021:
ALK announced the successful approval from FDA regarding short ragweed pollen allergen extract for the treatment of patients aged 5 to 65 years with short ragweed pollen-induced allergic rhinitis.
Future Outlook
Allergic Rhinitis Market Future Outlook
The Allergic Rhinitis Market size is projected to reach USD 18.44 Billion by 2035, growing at a CAGR of 3.72%, driven by increasing prevalence, innovative therapies, and rising awareness.
New opportunities lie in:
- Development of personalized immunotherapy solutions Expansion of telehealthservices for allergy management Investment in AI-driven diagnostic tools for early detection
By 2035, the market is expected to achieve robust growth, reflecting evolving consumer needs and technological advancements.
Market Segmentation
Allergic Rhinitis Market Type Outlook
- Seasonal Allergic Rhinitis
- Perennial Allergic Rhinitis
- Occupational Allergic Rhinitis
Allergic Rhinitis Market Treatment Outlook
- Antihistamines
- Corticosteroids
- Immunotherapy
- Decongestants
- Others
Allergic Rhinitis Market Route of Administration Outlook
- Oral
- Nasal & Others
Report Scope
| MARKET SIZE 2024 | 12.34(USD Billion) |
| MARKET SIZE 2025 | 12.8(USD Billion) |
| MARKET SIZE 2035 | 18.44(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.72% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | GlaxoSmithKline (GB), Boehringer Ingelheim (DE), Sanofi (FR), AstraZeneca (GB), Novartis (CH), Merck & Co. (US), Allergan (US), Bayer (DE), Teva Pharmaceutical Industries (IL) |
| Segments Covered | Type, Treatment, Route of Administration, Region |
| Key Market Opportunities | Advancements in biologics and personalized medicine enhance treatment options in the market. |
| Key Market Dynamics | Rising consumer awareness drives demand for innovative treatments in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Market Highlights
FAQs
What is the projected market valuation for the Allergic Rhinitis Market in 2035?
The projected market valuation for the Allergic Rhinitis Market in 2035 is 18.44 USD Billion.
What was the overall market valuation for the market in 2024?
What is the expected CAGR for the Allergic Rhinitis Market during the forecast period 2025 - 2035?
The expected CAGR for the Allergic Rhinitis Market during the forecast period 2025 - 2035 is 3.72%.
Which segment of allergic rhinitis had the highest valuation in 2024?
In 2024, the segment of Perennial Allergic Rhinitis had the highest valuation at 5.0 USD Billion.
What are the key treatment types in the Allergic Rhinitis Market?
Key treatment types in the Allergic Rhinitis Market include Antihistamines, Corticosteroids, Immunotherapy, and Decongestants.
Which company is a leading player in the market?
What was the valuation of the Seasonal Allergic Rhinitis segment in 2024?
How does the valuation of the Occupational Allergic Rhinitis segment compare to others?
What is the projected valuation for the Oral route of administration by 2035?
What is the anticipated growth trend for the Decongestants treatment segment?
Research Approach
Secondary Research
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), European Medicines Agency (EMA) Human Medicines Division, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, National Medical Products Administration (NMPA) China, National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID), National Center for Biotechnology Information (NCBI/PubMed), Cochrane Library, American Academy of Allergy Asthma & Immunology (AAAAI), European Academy of Allergy and Clinical Immunology (EAACI), British Society for Allergy and Clinical Immunology (BSACI), Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI), American Thoracic Society (ATS), European Respiratory Society (ERS), World Health Organization (WHO) Global Health Observatory, CDC National Center for Health Statistics (NHANES allergy prevalence data), IQVIA National Prescription Audit, EU Eurostat Health Database, and national health ministry reports from key markets. These sources were used to collect prescription statistics, epidemiological prevalence data, regulatory approval data (NDA/BLA filings), clinical safety and efficacy studies, immunotherapy treatment guidelines, and allergen surveillance reports for antihistamines, intranasal corticosteroids, sublingual immunotherapy (SLIT), subcutaneous immunotherapy (SCIT), and emerging biologic therapies.
Primary Research
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of Chief Medical Officers, VPs of Clinical Development, regulatory affairs chiefs, commercial directors, and portfolio managers from pharmaceutical manufacturers that were developing allergic rhinitis therapeutics and nasal drug delivery device companies. Pharmaceutical directors from hospital systems, procurement managers from specialty clinics and retail pharmacy chains, clinical immunology researchers, otolaryngologists (ENT specialists), pulmonary medicine specialists, and board-certified allergists/immunologists comprised demand-side sources. Primary research has validated pipeline stage gates (Phase III to commercialization), confirmed immunotherapy dosing protocols, and garnered insights on formulary placement strategies, generic substitution trends, and allergen immunology service adoption patterns.
Primary Respondent Breakdown:
By Designation: C-level Executives (30%), VP/Director Level (32%), Managers/Technical Leads/Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Market Size Estimation
Global market valuation was derived through revenue mapping and prescription volume analysis. The methodology included:
Identification of 35+ key pharmaceutical manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Product mapping across antihistamines (first-generation and second-generation), intranasal corticosteroids (INS), combination therapies (antihistamine/corticosteroid), subcutaneous immunotherapy (SCIT) extracts, sublingual immunotherapy (SLIT) tablets/drops, decongestants, and emerging biologics (anti-IgE, anti-IL-5/5R)
Analysis of reported and modeled annual revenues specific to allergic rhinitis portfolios, including prescription/data royalty streams from allergen extract immunotherapy
Coverage of manufacturers representing 80-85% of global market share in 2024
Extrapolation using bottom-up (prescription volume × average selling price by country/region, adjusted for generic penetration) and top-down (manufacturer revenue validation and IQVIA audit data reconciliation) approaches to derive segment-specific valuations for seasonal, perennial, and occupational allergic rhinitis treatment markets
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
